Empagliflozin is an SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. It works by helping the kidneys remove excess glucose through the urine while also promoting sodium and fluid excretion.

Benefits:

Helps lower blood glucose levels

Can support weight loss through urinary glucose loss

Reduces the risk of hospitalisation for heart failure

Provides kidney-protective benefits in appropriate patients

May help reduce cardiovascular risk

Potential Side Effects:

Increased urination and thirst

Dehydration or dizziness

Off-Label Uses:

May be used in certain patients with heart failure or kidney disease even when diabetes is not present, depending on the specific indication and product licensing.